Puupehenone Derivative Compositions for Drug-Resistant Pathogens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for drug-resistant Mycobacterium tuberculosis, Clostridioides difficile, and Enterococcus faecalis infections are lengthy and face increasing resistance, necessitating new compounds to target dormant bacilli and reduce toxin production.
Innovation Solution
Development of antimicrobial derivatives of (+)-Puupehenone, a marine natural product, with enhanced activity against drug-resistant strains, including ester derivatives and ring-open compounds synthesized through specific chemical routes, and formulation into pharmaceutical compositions for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard antibiotic treatments are used for drug-resistant tuberculosis, then treatment effectiveness is maintained, but treatment duration becomes excessively long (20-30 months)
Solution Approach 1:
The patent modifies the chemical structure of puupehenone by changing parameters such as adding ester groups at specific positions (e.g., 15-alpha-methoxypuupehenol, 15-cyanopuupehenone) to enhance antimicrobial activity. These structural parameter changes result in compounds with improved potency against dormant tuberculosis bacilli, enabling shorter treatment durations while maintaining effectiveness.
Solution Approach 2:
The patent creates composite antimicrobial agents by combining puupehenone core structure with various functional groups and molecular moieties (esters, cyanide groups, methoxy groups). These composite molecular structures exhibit synergistic effects that enhance antimicrobial activity against drug-resistant strains, allowing for reduced treatment duration without compromising reliability.
2Reliability
If marine natural product puupehenone is used as antimicrobial, then activity against dormant bacilli is achieved, but bioavailability and stability for clinical use are insufficient
Solution Approach 1:
The patent systematically modifies the chemical parameters of puupehenone by introducing ester groups, changing molecular weight, and adjusting functional groups to optimize pharmacokinetic properties. These parameter changes improve bioavailability and stability while preserving the core antimicrobial activity against dormant bacilli.
Solution Approach 2:
The patent employs ester derivatives as intermediary compounds that facilitate the transition from natural product to clinically usable formulation. These ester derivatives act as mediators that improve bioavailability and stability, serving as bridge compounds between the active natural product and its clinical applications.
3Reliability
If conventional antimicrobial drugs are used for Clostridioides difficulte, then treatment is effective, but resistance is developing and treatment options are limited
Solution Approach 1:
The patent segments the antimicrobial action by targeting specific vulnerabilities in different bacterial pathways. The puupehenone derivatives exhibit selective activity against specific bacterial processes (cell wall synthesis, protein synthesis) that are distinct from conventional antibiotic mechanisms, reducing the likelihood of cross-resistance and expanding treatment versatility.
Solution Approach 2:
The patent develops multi-functional antimicrobial compounds that can effectively target multiple bacterial species and mechanisms. The puupehenone derivatives demonstrate broad-spectrum activity including activity against C. difficile, E. faecalis, and M. tuberculosis, providing universal treatment capability across different pathogens and reducing adaptability issues.
4Reliability
If existing antimicrobial combinations are used for Enterococcus faecalis, then drug-sensitive strains are treated effectively, but drug-resistant strains emerge and treatment becomes more complex
Solution Approach 1:
The patent optimizes the chemical parameters of puupehenone derivatives to achieve enhanced potency against Enterococcus faecalis. By adjusting molecular structure (e.g., adding ester groups, modifying side chains), the compounds achieve effective concentrations that simplify treatment regimens while maintaining high effectiveness against both sensitive and resistant strains.
Data Source
AI summary
Provided herein are compositions to treat Clostridioides difficile (C. difficile), Mycobacterium tuberculosis (M. tuberculosis) and Enterococcus faecalis (E. faecalis). These compositions are related to the known compounds (+)-Puupehenone and (+)-ent-Chromazonarol, which are both naturally occurring products. The new compositions were shown to potently inhibit both growth and toxin production of C. difficile as well as inhibit the growth and survival of both replicating and dormant M. tuberculosis. In the United States the C. difficile burden is approximately 453,000 hospital cases and 29,000 deaths annually. Globally, about 10 million people fall ill from tuberculosis and 1.4 million died from the disease. In addition, the known compound (+)-ent-Chromazonarol (10) was found for the first time to strongly inhibit the growth of E. faecalis. E. faecalis has grown drug resistant to vancomycin. In 2017, Vancomycin-Resistant Enterococci (VRE) caused an estimated 54,500 infections among hospitalized patients and 5,400 estimated deaths in the United States.